Aporepair
Develops a therapeutic peptide for patients experiencing heart attacks
Highlights
- Young companyFounded 2023
- New on EvolcAdded 2026-11-10
About Aporepair
ApoRepair is developing APO-29, a therapeutic peptide intended to be administered alongside reopening a blocked artery during a heart attack.
The company is based in Montpellier, France, and was founded in 2023. Its laboratory is hosted at the Institute of Functional Genomics, a CNRS and Inserm research unit.
Product: APO-29, a therapeutic peptide in development for use alongside artery reopening during a heart attack.
Jobs at Aporepair
More biotech & pharma companies
Aqemia
AI drug discovery company using physics-based algorithms and generative AI to design and optimise drug moleculesNew on EvolcRemote-friendlyAtlanchim Pharma
Custom synthesis and analytical chemistry services for pharmaceutical, biotech, cosmetics and other research organizationsNew on EvolcAtlantic Bone Screen
Preclinical contract research services for pharmaceutical, biotech, biomaterials and nutraceutical developersNew on EvolcAzur Genetique
Forensic DNA identification lab in Nice serving French courts, the Gendarmerie and the Police NationaleNew on EvolcB Cell Design
Human Fc monoclonal antibodies and development services for diagnostic and biopharmaceutical companiesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
